About the Business
Incorporated in 2002, Symbiotec Pharmalab Limited is a leading pharmaceutical and biotechnology company focused on the development and manufacturing of Active Pharmaceutical Ingredients (APIs), specialty products, and nutritional ingredients. With over 30 years of operational experience starting from a lab-scale steroidal hormone API manufacturer in 1995, the company has transformed into a globally recognized, industrial-scale, backward-integrated platform.
Symbiotec operates two large-scale manufacturing facilities with chemical synthesis capacity of 584.67 metric tonnes (MT) and fermentation capacity of 300 kilolitres. Its units are certified by premier global regulatory authorities, including the United States FDA, European Union Good Manufacturing Practices (EU-GMP), and the Ministry of Food and Drug Safety, Korea.
- Global leadership in corticosteroid and steroidal hormone Active Pharmaceutical Ingredients (APIs).
- Vertically integrated manufacturing facilities with US FDA, EU-GMP, and international regulatory approvals.
- Long-standing relationships with tier-1 global pharmaceutical and wellness clients.
- Continuous R&D investments driving high-value, intellectual property-led product pipelines.
The company’s promoters are Anil Satwani, Kashish Satwani, Sushil Satwani, and Satwani Holdings LLP.
Financial Overview
Symbiotec Pharmalab Ltd. demonstrated steady financial performance, with total income growing by 15% and Profit After Tax (PAT) increasing by 14% between FY25 and FY26.
| Metric (₹ Cr) | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Total Income | ₹872.26 | ₹755.98 | ₹723.33 |
| EBITDA | ₹231.97 | ₹206.11 | ₹177.04 |
| PAT (Profit After Tax) | ₹109.90 | ₹96.79 | ₹100.06 |
| Net Worth | ₹1,158.64 | ₹821.15 | ₹720.68 |
| Reserves & Surplus | ₹1,145.95 | ₹810.03 | ₹709.54 |
| Total Borrowings | ₹387.91 | ₹540.92 | ₹247.21 |
| Total Assets | ₹1,780.79 | ₹1,579.65 | ₹1,294.79 |
Restated Consolidated Figures | Source: RHP Filings
Key Financial Metrics (FY26)
Issue Reservation
| Investor Category | Allocation Limit |
|---|---|
| QIB Shares Offered | Not more than 50% of the Net Offer |
| Retail (RII) Shares Offered | Not less than 35% of the Net Offer |
| NII (HNI) Shares Offered | Not less than 15% of the Net Offer |
Employee Discount: ₹90.00 per share is applicable for eligible employees.
Objects of the Issue
The net proceeds from the ₹150.00 Cr fresh issue are proposed to be utilized towards:
- Prepayment or scheduled repayment of certain outstanding borrowings ₹112.50 Cr
- General corporate purposes Balance
Symbiotec Pharmalab Limited brings strong technical capabilities and international regulatory credentials in specialized steroid and hormone APIs, generating high EBITDA margins of 26.59% and a PAT of ₹109.90 Cr in FY26.
Using ₹112.50 Cr of fresh issue proceeds for debt prepayment will strengthen its balance sheet and reduce finance costs. At an upper price band of ₹988, the issue is valued at a post-issue P/E of 56.81x with a market cap of ₹6,244.43 Cr. Investors looking for niche, export-oriented active pharmaceutical ingredient players can evaluate this issue for medium-to-long term portfolios.
